Wells Fargo’s Treace Medical Concepts TMCI Stock Holding History

Wells Fargo’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-55,300	Closed	-$1.39M	–	7698
2023 Q1	$1.39M	Buy	+55,300	New	+$1.3M	﹤0.01%	3148

Other funds holding TMCI

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CBU

CIBC Bancorp USA Chicago, Illinois $82.3B AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wells Fargo's TMCI Position: Q2 2026 in Review

Wells Fargo sold out of Treace Medical Concepts (TMCI) in Q2 2026, closing a stake of 17,543 shares — an estimated $23.5K sold.

Wells Fargo first reported a position in TMCI in Q2 2021 and held it in 20 quarters. The position peaked at $3.05M in Q3 2021. 116 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

Wells Fargo reported no remaining Treace Medical Concepts position as of Q2 2026 after selling out during the quarter.
Wells Fargo sold 17,543 Treace Medical Concepts shares in Q2 2026, an estimated $23.5K.
Wells Fargo first reported a position in Treace Medical Concepts in Q2 2021 and held it in 20 quarters.
Wells Fargo's Treace Medical Concepts position peaked at $3.05M in Q3 2021.
116 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.